S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Argentina's populist president meets billionaire Elon Musk in Texas — and a bromance is born
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
It's almost April 15. Here's how to reduce stress and get your taxes done
Nearing 50 Supreme Court arguments in, lawyer Lisa Blatt keeps winning
How O.J. Simpson burned the Ford Bronco into America's collective memory
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Argentina's populist president meets billionaire Elon Musk in Texas — and a bromance is born
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
It's almost April 15. Here's how to reduce stress and get your taxes done
Nearing 50 Supreme Court arguments in, lawyer Lisa Blatt keeps winning
How O.J. Simpson burned the Ford Bronco into America's collective memory
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Argentina's populist president meets billionaire Elon Musk in Texas — and a bromance is born
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
It's almost April 15. Here's how to reduce stress and get your taxes done
Nearing 50 Supreme Court arguments in, lawyer Lisa Blatt keeps winning
How O.J. Simpson burned the Ford Bronco into America's collective memory
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Argentina's populist president meets billionaire Elon Musk in Texas — and a bromance is born
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
It's almost April 15. Here's how to reduce stress and get your taxes done
Nearing 50 Supreme Court arguments in, lawyer Lisa Blatt keeps winning
How O.J. Simpson burned the Ford Bronco into America's collective memory

C4 Therapeutics (CCCC) Competitors

$7.41
-0.38 (-4.88%)
(As of 04/12/2024 ET)

CCCC vs. VALN, VYGR, TSHA, ALEC, TRML, EDIT, SLDB, ITOS, REPL, and ADPT

Should you be buying C4 Therapeutics stock or one of its competitors? The main competitors of C4 Therapeutics include Valneva (VALN), Voyager Therapeutics (VYGR), Taysha Gene Therapies (TSHA), Alector (ALEC), Tourmaline Bio (TRML), Editas Medicine (EDIT), Solid Biosciences (SLDB), iTeos Therapeutics (ITOS), Replimune Group (REPL), and Adaptive Biotechnologies (ADPT). These companies are all part of the "biological products, except diagnostic" industry.

C4 Therapeutics vs.

Valneva (NASDAQ:VALN) and C4 Therapeutics (NASDAQ:CCCC) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability, analyst recommendations, media sentiment and community ranking.

Valneva presently has a consensus price target of $21.67, indicating a potential upside of 154.60%. C4 Therapeutics has a consensus price target of $10.25, indicating a potential upside of 38.33%. Given C4 Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Valneva is more favorable than C4 Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Valneva
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00
C4 Therapeutics
0 Sell rating(s)
3 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50

Valneva has higher revenue and earnings than C4 Therapeutics. Valneva is trading at a lower price-to-earnings ratio than C4 Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Valneva$153.71M3.85-$109.78M-$1.58-5.39
C4 Therapeutics$20.76M24.49-$132.49M-$2.67-2.78

In the previous week, C4 Therapeutics had 6 more articles in the media than Valneva. MarketBeat recorded 10 mentions for C4 Therapeutics and 4 mentions for Valneva. C4 Therapeutics' average media sentiment score of 0.88 beat Valneva's score of 0.04 indicating that Valneva is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Valneva
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
C4 Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
2 Very Negative mention(s)
Neutral

Valneva has a net margin of -65.99% compared to Valneva's net margin of -638.34%. Valneva's return on equity of -55.30% beat C4 Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Valneva-65.99% -59.48% -19.17%
C4 Therapeutics -638.34%-55.30%-35.80%

C4 Therapeutics received 2 more outperform votes than Valneva when rated by MarketBeat users. However, 51.16% of users gave Valneva an outperform vote while only 37.50% of users gave C4 Therapeutics an outperform vote.

CompanyUnderperformOutperform
ValnevaOutperform Votes
22
51.16%
Underperform Votes
21
48.84%
C4 TherapeuticsOutperform Votes
24
37.50%
Underperform Votes
40
62.50%

Valneva has a beta of 2.25, suggesting that its share price is 125% more volatile than the S&P 500. Comparatively, C4 Therapeutics has a beta of 3.18, suggesting that its share price is 218% more volatile than the S&P 500.

11.4% of Valneva shares are held by institutional investors. Comparatively, 78.8% of C4 Therapeutics shares are held by institutional investors. 14.9% of Valneva shares are held by company insiders. Comparatively, 8.0% of C4 Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Valneva beats C4 Therapeutics on 10 of the 17 factors compared between the two stocks.

Get C4 Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CCCC and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CCCC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CCCC vs. The Competition

MetricC4 TherapeuticsBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$508.33M$2.60B$4.87B$7.64B
Dividend YieldN/A2.25%2.93%3.91%
P/E Ratio-2.7826.74216.3916.52
Price / Sales24.49339.942,405.5195.00
Price / CashN/A153.0436.8531.69
Price / Book1.824.024.604.29
Net Income-$132.49M-$45.26M$104.37M$214.71M
7 Day Performance-1.46%-2.43%-2.29%-2.30%
1 Month Performance-30.94%-2.85%-2.16%-1.58%
1 Year Performance125.23%13.50%14.23%7.82%

C4 Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VALN
Valneva
1.479 of 5 stars
$7.56
-1.6%
$21.67
+186.6%
-26.8%$525.12M$165.52M-4.78676Positive News
Gap Down
VYGR
Voyager Therapeutics
4.1408 of 5 stars
$9.91
-6.0%
$19.33
+95.1%
+7.8%$538.11M$250.01M3.21162Short Interest ↑
TSHA
Taysha Gene Therapies
2.3859 of 5 stars
$2.71
-4.6%
$6.57
+142.5%
+335.2%$506.82M$15.45M-1.0552Analyst Report
News Coverage
ALEC
Alector
3.6967 of 5 stars
$5.82
-5.5%
$14.50
+149.1%
-4.4%$557.27M$97.06M-3.75244Short Interest ↑
News Coverage
Gap Down
TRML
Tourmaline Bio
2.0498 of 5 stars
$21.80
-7.4%
$61.80
+183.5%
N/A$559.17MN/A-1.9219Short Interest ↑
News Coverage
EDIT
Editas Medicine
3.567 of 5 stars
$6.87
-5.6%
$15.00
+118.3%
-2.4%$562.04M$78.12M-3.35265Short Interest ↑
Gap Down
SLDB
Solid Biosciences
3.7412 of 5 stars
$12.10
-2.7%
$18.25
+50.8%
+97.9%$456.90M$8.09M-2.5088Short Interest ↑
ITOS
iTeos Therapeutics
2.1512 of 5 stars
$12.68
-4.9%
$30.33
+139.2%
-9.4%$454.45M$12.60M-4.03157
REPL
Replimune Group
4.4788 of 5 stars
$7.13
-7.8%
$39.25
+450.5%
-54.4%$437.71MN/A-2.26284Gap Down
ADPT
Adaptive Biotechnologies
3.8227 of 5 stars
$2.98
-4.2%
$7.25
+143.3%
-63.1%$432.37M$170.28M-1.91709Short Interest ↑

Related Companies and Tools

This page (NASDAQ:CCCC) was last updated on 4/13/2024 by MarketBeat.com Staff

From Our Partners